crysvita burosumab 30 mg/ml solution for injection in a 5 ml vial
kyowa kirin australia pty ltd - burosumab, quantity: 30 mg - injection, solution - excipient ingredients: sorbitol; histidine; methionine; polysorbate 80; water for injections; hydrochloric acid - crysvita (burosumab) is indicated for the treatment of x-linked hypophosphataemia (xlh) in adults, adolescents and children 1 year of age or older.
crysvita burosumab 20 mg/ml solution for injection in a 5 ml vial
kyowa kirin australia pty ltd - burosumab, quantity: 20 mg - injection, solution - excipient ingredients: sorbitol; histidine; methionine; polysorbate 80; water for injections; hydrochloric acid - crysvita (burosumab) is indicated for the treatment of x-linked hypophosphataemia (xlh) in adults, adolescents and children 1 year of age or older.
crysvita burosumab 10 mg/ml solution for injection in a 5 ml vial
kyowa kirin australia pty ltd - burosumab, quantity: 10 mg - injection, solution - excipient ingredients: sorbitol; histidine; methionine; polysorbate 80; water for injections; hydrochloric acid - crysvita (burosumab) is indicated for the treatment of x-linked hypophosphataemia (xlh) in adults, adolescents and children 1 year of age or older.
fresofol 1% mct/lct propofol 1000mg/100ml emulsion for intravenous injection/infusion vial
fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; water for injections; glycerol; sodium hydroxide; soya oil; egg lecithin; oleic acid - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.
fresofol 1% mct/lct propofol 500mg/50ml emulsion for intravenous injection/infusion vial
fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; egg lecithin; sodium hydroxide; water for injections; oleic acid; glycerol; soya oil - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.
fresofol 1% mct/lct propofol 200mg/20ml emulsion for intravenous injection/infusion ampoule
fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; sodium hydroxide; water for injections; glycerol; oleic acid; soya oil; egg lecithin - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.
fresofol 1% mct/lct propofol 200mg/20ml emulsion for intravenous injection/infusion vial
fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: glycerol; sodium hydroxide; egg lecithin; medium chain triglycerides; soya oil; oleic acid; water for injections - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.
briviact brivaracetam 50mg/5ml injection vial
ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium acetate trihydrate; glacial acetic acid; water for injections - briviact solution for injection is indicated as add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy.
copaxone glatiramer acetate 40 mg/1 ml solution for injection prefilled syringe
teva pharma australia pty ltd - glatiramer acetate, quantity: 40 mg - injection, solution - excipient ingredients: mannitol; water for injections - copaxone is indicated for the: 1- reduction of the frequency of relapses in patients with relapsing remitting multiple sclerosis. 2-treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent mri lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.
tranexamic acid lu 500 mg/ 5 ml tranexamic acid solution for injection ampoule
luminarie pty ltd - tranexamic acid, quantity: 100 mg/ml - injection, solution - excipient ingredients: water for injections - adults,for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.